ConductScience.org, home

Paper3948308

Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.

Dorr RT and 2 others. Cancer Chemother Pharmacol, 1986. Cited by 23 papers, by iCite.

Cite this record

ConductScience Library. Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone. Papers, record 3948308. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3948308

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Lack of experimental vesicant activity for the anticancer agents cisplatin, melphalan, and mitoxantrone.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1986
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
23
iCite
Relative citation ratio, by iCite
1.6
iCite
Revised in PubMed
2019-08-29
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Dorr RTR T
2Alberts DSD S
3Soble MM

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AnthraquinonesMajor topic
CisplatinMajor topic
IrritantsMajor topic
MelphalanMajor topic
Skin UlcerMajor topic
Animals
Drug Evaluation, Preclinical
Female
Injections, Intradermal
Mice
Mice, Inbred BALB C
Mitoxantrone

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA-17094NCI NIH HHSUnited StatesP01CA017094PubMed and NIHNIH RePORTER
CA-23074NCI NIH HHSUnited StatesP30CA023074PubMed and NIHNIH RePORTER
CA-31078NCI NIH HHSUnited StatesR01CA031078PubMed and NIHNIH RePORTER

Download CSV of grants

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17442269Experimental model of doxorubicin extravasation in the mouse.J Pharmacol Methods1980https://conductscience.org/library/papers/7442269PubMed
23978648Disposition of mitoxantrone in cancer patients.Cancer Res1985https://conductscience.org/library/papers/3978648PubMed
36681733Full-thickness skin necrosis due to inadvertent interstitial infusion of cisplatin.Cancer Treat Rep1983https://conductscience.org/library/papers/6681733PubMed
46708933Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.Mol Pharmacol1984https://conductscience.org/library/papers/6708933PubMed
56362875Clinical safety and tolerance of mitoxantrone (Novantrone).Cancer Treat Rev1983https://conductscience.org/library/papers/6362875PubMed
67397706Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs.Cancer Treat Rev1980https://conductscience.org/library/papers/7397706PubMed
76678864Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.Invest New Drugs1983https://conductscience.org/library/papers/6678864PubMed
86102140Mechanism of DNA-binding of some aminoalkylamino-derivatives of anthraquinone and naphthacenequinone.J Pharm Pharmacol1980https://conductscience.org/library/papers/6102140PubMed
9427822Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience.Cancer Treat Rep1979https://conductscience.org/library/papers/427822PubMed
103995475A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.Cancer1985https://conductscience.org/library/papers/3995475PubMed
117083234Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).Cancer Treat Rep1982https://conductscience.org/library/papers/7083234PubMed
12953958Skin ulcers due to adriamycin.Cancer1976https://conductscience.org/library/papers/953958PubMed
136732077Intraperitoneal chemotherapy with melphalan.Ann Intern Med1984https://conductscience.org/library/papers/6732077PubMed
14445964Kinetics of intravenous melphalan.Clin Pharmacol Ther1979https://conductscience.org/library/papers/445964PubMed
157042076Treatment of tissue extravasation by antitumor agents.Cancer1982https://conductscience.org/library/papers/7042076PubMed
16481319Inapparent infiltrations associated with vindesine administration.Med Pediatr Oncol1979https://conductscience.org/library/papers/481319PubMed
176401597Mitomycin C extravasation injuries.Cancer1983https://conductscience.org/library/papers/6401597PubMed
187460190Phase I clinical trial f mitoxantrone: a new anthracenedione anticancer drug.Cancer Chemother Pharmacol1980https://conductscience.org/library/papers/7460190PubMed
19326117Cis-diamminedichloroplatinum (II). A new anticancer drug.Ann Intern Med1977https://conductscience.org/library/papers/326117PubMed
207193090Cellulitis and fibrosis due to cis-diamminedichloroplatinum(II) (platinol) infiltration.Cancer Treat Rep1980https://conductscience.org/library/papers/7193090PubMed

See all 28 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 23 citations.

PMIDTitleJournalYearIn PapersSource
40443182
Comparison of outcomes in feline intermediate- to large-cell lymphoma treated with CMOP (cyclophosphamide, mitoxantrone, vincristine and prednisolone) instead of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone).
J Feline Med Surg2025https://conductscience.org/library/papers/40443182PubMed
8820798Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.Drugs Aging1996https://conductscience.org/library/papers/8820798PubMed
8339386Extravasation injury potential of CI-980, a novel synthetic mitotic inhibitor.Cancer Chemother Pharmacol1993https://conductscience.org/library/papers/8339386PubMed
1711446Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs1991https://conductscience.org/library/papers/1711446PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3948308

GET https://conductscience.org/api/papers/v1/3948308/references?page=2